SCHEMBL13917174

SCHEMBL13917174

Nc1cccc(Nc2nc(NCCCCCO)nc(Nc3cccc(N)c3)n2)c1

nearest known ligand 0.70

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KCNH3 Q9ULD8 9/20 0.70
▸ FCGR3B O75015 1/20 0.63
▸ FCGR1A P12314 1/20 0.63
▸ FCGR2A P12318 1/20 0.63
▸ RECQL P46063 1/20 0.52
▸ MCL1 Q07820 1/20 0.52
▸ CA12 O43570 1/20 0.49
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49
▸ CA9 Q16790 1/20 0.49
▸ CA14 Q9ULX7 1/20 0.49
▸ GBA1 P04062 3/20 0.47
▸ CDK1 P06493 1/20 0.46
▸ KDR P35968 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13921863 1.00 KCNH3 (0.70) KCNH3FCGR3BFCGR1AFCGR2ARECQL
SCHEMBL13921821 0.99 KCNH3 (0.68) KCNH3FCGR3BFCGR1AFCGR2ARECQL
SCHEMBL13921833 0.92 FCGR3B (0.67) KCNH3FCGR3BFCGR1AFCGR2ARECQL
SCHEMBL13921832 0.91 FCGR3B (0.80) KCNH3FCGR3BFCGR1AFCGR2ARECQL
SCHEMBL13917179 0.89 FCGR3B (0.81) KCNH3FCGR3BFCGR1AFCGR2ARECQL
SCHEMBL13921814 0.89 FCGR3B (0.77) KCNH3FCGR3BFCGR1AFCGR2ARECQL
SCHEMBL13921815 0.88 FCGR3B (0.55) KCNH3FCGR3BFCGR1AFCGR2ARECQL
SCHEMBL13421097 0.87 FCGR3B (0.75) KCNH3FCGR3BFCGR1AFCGR2ARECQL
SCHEMBL13421092 0.86 FCGR3B (0.81) KCNH3FCGR3BFCGR1AFCGR2ARECQL
SCHEMBL13421089 0.84 FCGR3B (0.70) KCNH3FCGR3BFCGR1AFCGR2ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090075867-A1 Triazine compounds and compositions thereof for the treatment of cancers PROMETIC BIOSCIENCE INC. (CA) 2009-03-19 — — US disclosed
US-20090068169-A1 2,4,6-triamino-s-triazine-based compounds which bind to the tail (fc) portion of immunoglobulins and their use PROMETIC BIOSCIENCES INC. (CA) 2009-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090068169-A1 2,4,6-triamino-s-triazine-based compounds which bind to the tail (fc) portion of immunoglobulins and their use FCGR2A, FCGR3B, FCGR1A KCNH3 1915/4885FCGR3B 2/4885FCGR1A 3/4885
US-20090075867-A1 Triazine compounds and compositions thereof for the treatment of cancers MCTS1, TYR, BRAF KCNH3 3451/4885FCGR3B 4723/4885FCGR1A 4810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback